AngioDynamics (NASDAQ:ANGO) Updates FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of -0.380–0.340 for the period, compared to the consensus estimate of -0.400. The company issued revenue guidance of $282.0 million-$288.0 million, compared to the consensus revenue estimate of $283.9 million.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a research report on Tuesday, December 10th. Canaccord Genuity Group cut their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th.

AngioDynamics Stock Up 1.4 %

NASDAQ ANGO opened at $9.40 on Wednesday. AngioDynamics has a fifty-two week low of $5.26 and a fifty-two week high of $9.63. The business has a 50 day moving average price of $7.82 and a two-hundred day moving average price of $7.27. The stock has a market cap of $381.96 million, a PE ratio of -1.54 and a beta of 0.59.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.